Abstract
Neurodegenerative disorders (NDDs) are characterized by the progressive loss of structure or neuron function, often associated with neuronal death. Treatments for neurodegenerative diseases only address symptoms without having any disease-modifying effect but serious side effects. Currently, there is no effective treatment for NDDs. This is due to the poor flow of drugs to the blood-barrier brain (BBB) which does not allow macromolecules like proteins and peptides to pass through it. Targeted drug delivery to the central nervous system (CNS) for the diagnosis and treatment of NDDs, such as Alzheimer’s disease (AD), is restricted due to the limitations posed by the BBB as well as opsonization by plasma proteins in the systemic circulation and peripheral side-effects. Nanotechnology thereby presents a broad approach for transporting molecules through the BBB, thus allowing the entry of substances acting directly on the site affected by the disease. The aim of this review is to outline current strategies in nanotechnology for treating Alzheimer’s and Parkinson’s diseases.
Keywords: Alzheimer’s disease (AD), astrocyte, Blood-brain barrier (BBB), glial cell, Parkinson’s disease (PD), nanotechnology, drug delivery, nanoparticle (NP), liposome, dendrimer, quantum dot, nanocarrier, nanoliposome, nanomicelle.
Current Pharmaceutical Design
Title:Alzheimer’s Disease and Parkinson’s Disease: A Review of Current Treatment Adopting a Nanotechnology Approach
Volume: 24 Issue: 1
Author(s): Adriana Trompetero, Aldemar Gordillo, Mora Carolina del Pilar, Velasquillo María Cristina and Rosa Helena Bustos Cruz*
Affiliation:
- Universidad de la Sabana, Faculty of Medicine, Therapeutic Evidence Group, Chía,Colombia
Keywords: Alzheimer’s disease (AD), astrocyte, Blood-brain barrier (BBB), glial cell, Parkinson’s disease (PD), nanotechnology, drug delivery, nanoparticle (NP), liposome, dendrimer, quantum dot, nanocarrier, nanoliposome, nanomicelle.
Abstract: Neurodegenerative disorders (NDDs) are characterized by the progressive loss of structure or neuron function, often associated with neuronal death. Treatments for neurodegenerative diseases only address symptoms without having any disease-modifying effect but serious side effects. Currently, there is no effective treatment for NDDs. This is due to the poor flow of drugs to the blood-barrier brain (BBB) which does not allow macromolecules like proteins and peptides to pass through it. Targeted drug delivery to the central nervous system (CNS) for the diagnosis and treatment of NDDs, such as Alzheimer’s disease (AD), is restricted due to the limitations posed by the BBB as well as opsonization by plasma proteins in the systemic circulation and peripheral side-effects. Nanotechnology thereby presents a broad approach for transporting molecules through the BBB, thus allowing the entry of substances acting directly on the site affected by the disease. The aim of this review is to outline current strategies in nanotechnology for treating Alzheimer’s and Parkinson’s diseases.
Export Options
About this article
Cite this article as:
Trompetero Adriana , Gordillo Aldemar, del Pilar Carolina Mora , Cristina María Velasquillo and Bustos Cruz Helena Rosa*, Alzheimer’s Disease and Parkinson’s Disease: A Review of Current Treatment Adopting a Nanotechnology Approach, Current Pharmaceutical Design 2018; 24 (1) . https://dx.doi.org/10.2174/1381612823666170828133059
DOI https://dx.doi.org/10.2174/1381612823666170828133059 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Targets in Multiple Sclerosis: To Oxidative Stress and Beyond
Current Topics in Medicinal Chemistry Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging
Mini-Reviews in Medicinal Chemistry Anti-Viral Agents in Neurodegenerative Disorders: New Paradigm for Targeting Alzheimer’s Disease
Recent Patents on Anti-Infective Drug Discovery The Cardiovascular Nutrapharmacology of Resveratrol: Pharmacokinetics, Molecular Mechanisms and Therapeutic Potential
Current Medicinal Chemistry Conformations and Assembly of Amyloid Oligomers by Electrospray Ionisation - Ion Mobility Spectrometry - Mass Spectrometry
Current Analytical Chemistry Fluoxetine Improves Behavioral Performance by Suppressing the Production of Soluble β-Amyloid in APP/PS1 Mice
Current Alzheimer Research Patent Selections
Recent Patents on Regenerative Medicine Conformational Diseases and Structure-Toxicity Relationships: Lessons from Prion-Derived Peptides
Current Protein & Peptide Science Pharmacological Approaches to Targeting Muscarinic Acetylcholine Receptors
Recent Patents on CNS Drug Discovery (Discontinued) Human Umbilical Cord Mesenchymal Stem Cell Therapy on Neuromyelitis Optica
Current Neurovascular Research Mitochondrial Aconitase in Neurodegenerative Disorders: Role of a Metabolism- related Molecule in Neurodegeneration
Current Drug Targets Reversal of Bone Cancer Pain by HSV-1-Mediated Silencing of CNTF in an Afferent Area of the Spinal Cord Associated with AKT-ERK Signal Inhibition
Current Gene Therapy Micro Arrays and Biochips: Applications and Potential in Genomics and Proteomics
Current Genomics Antioxidant Effects of Natural Bioactive Compounds
Current Pharmaceutical Design D-amino Acids as Novel Blood-based Biomarkers
Current Medicinal Chemistry Oxidative Stress Protection by Novel Telomerase Activators in Mesenchymal Stem Cells Derived from Healthy and Diseased Individuals
Current Molecular Medicine Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD
Current Alzheimer Research MicroRNAs in CAG Trinucleotide Repeat Expansion Disorders: an Integrated Review of the Literature
CNS & Neurological Disorders - Drug Targets Polyglutamine and Neurodegeneration: Structural Aspects
Protein & Peptide Letters Anthony L. Fink (1943-2008): Scientist, Teacher and Artist
Current Protein & Peptide Science